Novo Nordisk stock news
On July 10, 2026, Novo Nordisk officially launched Awiqli (insulin icodec) in India, marking the commercial availability of the world's first once--weekly basal insulin in a key growth market. The therapy, indicated for adults with Type 1 and Type 2 diabetes, reduces the annual injection burden from 365 to 52 doses. This launch is expected to improve treatment adherence and address the significant delay in insulin initiation in India, where the company aims to double its insulin user base over the next six to seven years.